Joint ICTP-IAEA Workshop on Dosimetry in Radionuclide Therapy and Diagnostic Nuclear Medicine | (smr 3570)
Starts 20 Sep 2021
Ends 1 Oct 2021
Central European Time
Online -
Online
An ICTP-IAEA Virtual Meeting
In recent years, there has been an increase of therapeutic applications using radiopharmaceuticals. This workshop, which is intended for clinically qualified medical physicists with experience in radionuclide therapy, will provide the participants with a comprehensive review of the developments in the field of nuclear medicine image quantification and practical internal dosimetry.
The purpose of this workshop is to contribute to the knowledge of clinically qualified medical physicists in nuclear medicine by providing theoretical and practical tools for internal dosimetry. Molecular radiotherapy has demonstrated unique therapeutic advantages in the treatment of an increasing number of cancer types. Such treatments can deliver high absorbed doses to specific targets (tumour lesions) and healthy organs (organs at risk) and, thus, require a patient specific dose assessment. These calculations would help to optimize the amount of radioactivity to be administered and to reduce the risk of under- or over-dosing patients, otherwise observed when using empirical approaches to activity determination. As part of the selection, candidates will be requested to undertake a written test.
The workshop is under the umbrella of ICTP and IAEA and is expected to strengthen the knowledge of clinically qualified medical physicists working in nuclear medicine. The expected audience are clinically qualified medical physicists working in a hospital, with at least 5 years’ experience in the field of nuclear medicine medical physics including radionuclide therapy.
Topics:
Introduction to radiopharmaceutical dosimetry and MIRD formalism
Time integrated activity coefficient calculation
Radiation transport and energy deposition
ICRP Internal dose coefficient for radiological protection
Y-90 microspheres dosimetry
Bone seeking radiopharmaceuticals (including Ra223 therapy)
Peptide receptor radionuclide therapy
I131 therapy
Radiation safety for staff and the public in therapeutic nuclear medicine
Lecturers:
M. BARDIES, Cancer Research Institute of Montpellier U1194 INSERM/ICM/Montpellier University, France
W. BOLCH, Advanced Laboratory for Radiation Dosimetry Studies, J. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, USA
C. CHIESA, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy
M. CREMONESI, Istituto Europeo di Oncologia, IRCCS, Milano, Italy
L. FERRER, ICO René Gauducheau, Saint Herblain, France
F. GIAMMARILE, IAEA, Austria
G. GLATTING, Abteilung für Nuklearmedizin | Medizinische Strahlenphysik, University Ulm, Ulm, Germany
R. HOBBS, Department of Radiation Oncology and Molecular Radiation Sciences Johns Hopkins Medical Institution, Baltimore, USA
M. LASSMANN, Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Austria
G. LORETI, IAEA, Austria
L. STRIGARI, Department of Medical Physics, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy
A. VERGARA-GIL, CRCT, Toulouse, France